Name: UMIN ID:
Unique ID issued by UMIN | UMIN000016550 |
---|---|
Receipt number | R000019209 |
Scientific Title | Untreated IIIB/IV period with the EGFR mutation in the gene, phase II study of Gefitinib and the pemetrexed / bevacizumab combination maintenance therapy after Gefitinib and the cisplatin / pemetrexed / bevacizumab combination induction therapy for non-squamous epithelium non-small cell lung cancer of the latter recurrence |
Date of disclosure of the study information | 2015/02/16 |
Last modified on | 2016/08/17 16:13:22 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2015/02/16 14:53:05 | ||
2 | Update | 2016/08/17 10:17:49 | UMIN ID1 |
|
3 | Update | 2016/08/17 16:13:23 | Organization Organization Division name Division name Address Address TEL Last name of contact person Last name of contact person Organization Organization Division name Division name Address Address TEL Name of person sending information Name of person sending information Organization Organization Division name Division name Address Address TEL Name of primary person or sponsor Institute Institute Department Organization Post marketing survey by drug manufacture etc., specified by Japanese law. Organization1 Address1 Tel1 Email1 Institutions |